Navigation Links
Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial

Vical Incorporated announced today that an Ebola vaccine candidate administered using Vical's proprietary DNA delivery technology was safe and well tolerated, and produced both antibody and T-cell Ebola-specific responses in all healthy volunteers who received the full 3 doses of vaccine.

The Phase 1, randomized, placebo-controlled, dose-escalation study, the first human trial for any Ebola vaccine, was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and conducted at the NIH Clinical Center. The data were presented at the American Society for Microbiology (ASM) 2006 Biodefense Research Meeting in Washington, D.C., by Julie E. Martin, D.O., a trial investigator and research scientist at NIAID's Dale and Betty Bumpers Vaccine Research Center (VRC), which developed the vaccine. The DNA vaccine used in the Phase 1 trial incorporates genetic material encoding core and surface proteins from two strains of Ebola. Vical has secured a nonexclusive license from the NIH to proprietary gene sequences used in the vaccine.

"The high rates of immune responses at all dose levels in this initial human Ebola vaccine study support continued development of this vaccine and further evaluation of our technology for potential additional biodefense and emerging disease applications," said David C. Kaslow, M.D., Vical's Chief Scientific Officer, "particularly where antibody responses may be protective. Our processes allow rapid development and manufacturing of vaccines without handling potentially dangerous pathogens."

The vaccine used in the Phase 1 trial vaccine included three plasmids (closed loops of DNA), one each encoding the surface glycoprotein (GP) from the Zaire strain of Ebola, GP from the Sudan/Gulu strain, and the internal nucleoprotein (NP) from the Zaire strain. Subjects received three doses of vaccine or placebo at one-month intervals via intramuscular needleless injection. Three coh orts tested progressively higher doses of the vaccine at 2 mg (5 subjects), 4 mg (8 subjects), or 8 mg (8 subjects ?with 6 receiving the full three doses). Each cohort included two additional subjects who received placebo instead of active vaccine.

The vaccine was well tolerated, with no severe adverse reactions to the vaccine reported at any of the doses tested. Ebola-specific antibody responses against at least one of the encoded antigens were detected in all vaccine recipients. GP-specific antibody and T-cell responses were detected in all recipients who received the full three doses at all dose levels.


'"/>

Source:Porter Novelli, Life Sciences


Related biology news :

1. Study Links Ebola Outbreaks To Animal Carcasses
2. Scientists discover how Ebola virus infects cells
3. Ebola virus: from wildlife to dogs
4. Poaching, logging, and outbreaks of Ebola threaten central African gorillas and chimpanzees
5. Gene-specific Ebola therapies protect non-human primates from lethal disease
6. Gorilla susceptibility to Ebola virus: the cost of sociality
7. Researchers discover key mechanism by which lethal viruses Ebola and Marburg cause disease
8. Pattern of human Ebola outbreaks linked to wildlife and climate
9. Ebola-outbreak kills 5000 gorillas
10. Ebola outbreaks killing thousands of gorillas and chimpanzees
11. Research advances quest for HIV-1 vaccine
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... SAN DIEGO and BEIJING ... Ltd., a leading commercial provider of genomic services and ... expertise, announced today that it has completed a USD ... China Merchants Bank Co., Ltd.,s CMB International Capital Management ... SDIC Innovation Investment Management Co., Ltd. ("SDIC Innovation") and ...
(Date:11/30/2016)... Mass. , Nov. 30, 2016   Merck ... that it has entered into a set of agreements ... services for Merck,s collection of genetic reagents such as ... with Evotec,s screening expertise offers an accelerated pathway to ... discovery starts with the identification of new targets, a ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... development of a new orally administered treatment for Alzheimer’s disease (AD), today announced ... a Phase 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s patients ...
(Date:11/30/2016)... ... November 30, 2016 , ... ProMIS Neurosciences (“ProMIS” or the ... diseases, today announced that all five of its validated monoclonal antibody (mAb) therapeutic ... toxic, prion-like forms of Amyloid beta (Aß) in vitro. , “We previously demonstrated ...
Breaking Biology Technology: